Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Julphar
Cipla
McKinsey
Colorcon
McKesson

Generated: September 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 10,206,877

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,206,877
Title:Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.
Inventor(s): Phenix; Brian Dean (Acton, MA), Bagnol; Laurent Jean-Claude (Burlington, MA), Brodeur; Geoffrey Glen (Somerville, MA), Chandran; Sachin (Somerville, MA), Dokou; Eleni (Cambridge, MA), Ferris; Lori Ann (Medford, MA), Knezic; Dragutin (Watertown, MA), McCarty; Katie Lynn (Watertown, MA), Medek; Ales (Winchester, MA), Waggener; Sara A. (N. Billerica, MA)
Assignee: Vertex Pharmaceuticals Incorporated (Boston, MA)
Application Number:14/686,117
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Dosage form;

Drugs Protected by US Patent 10,206,877

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Vertex Pharms Inc SYMDEKO (COPACKAGED) ivacaftor; ivacaftor, tezacaftor TABLET, TABLET;ORAL 210491-001 Feb 12, 2018 RX Yes Yes   Try a Free Trial   Try a Free Trial Y TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Chubb
QuintilesIMS
Johnson and Johnson
Healthtrust
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.